Jubilant Life Sciences net profit jumps to 67% at Rs 210 cr during Q2

While the company had posted a net profit of Rs 125.47 crore during the same period a year ago, it has recorded a comparatively robust performance in the second quarter of current financial year


New Delhi: Jubilant Life Sciences has announced 67.18 percent rise in its consolidated net profit to Rs 209.77 crore for the quarter ended September 30. The company had posted a net profit of Rs 125.47 crore in the year-ago period.

Total revenue from operations stood at Rs 2,269.49 crore for the reported quarter. It was Rs 1,642.04 crore for the same period a year ago.

In a joint statement, Company’s Chairman, Shyam S Bhartia and Co-Chairman and MD, Hari S Bhartia mentioned, “The record performance in the company’s pharmaceutical segment has been led by continued growth in specialty pharmaceuticals and smart recovery in Generics and API businesses.”

“Demand in our Life Science Ingredients (LSI) segment remains strong. The company is confident of delivering better results and is focussed on continued strengthening of its balance sheet, going forward,” the top management’s statement added.

As per Jubilant, its pharmaceuticals revenue are at Rs 1,326 crore for the reported quarter, contributing 58 per cent to the total revenue, up 55 per cent year-on-year. Life Sciences Ingredient revenue stood at Rs 887 crore, contributing 39 per cent to the total revenue pack, up 20 per cent year-on-year, it added.

Other segments’ revenue was at Rs 57 crore, up 15 per cent from the year-ago period. International revenues for the quarter were at Rs 1,618 crore, contributing 71 per cent to the total revenue, the company said.